Latest Conference Content

Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

Patients with moderate-to-severe plaque psoriasis experienced early and sustained improvements through 108 weeks of treatment.

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

Various speakers comment on why meetings like the Society for Pediatric Dermatology (SPD) 2024 Annual Meeting are important for the advancement of pediatric dermatology.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, takes a look at the major sources spreading dermatology misinformation to children, including social media.

Nichole Halliburton, APRN, CNP, a family nurse practitioner at the Cincinnati Children's Hospital Medical Center, explains the ways that patient education, parents and caregivers, and emerging technologies can help improve the quality of pediatric dermatology care.

Rebecca Flynn, MSN, APRN, CPNP-PC, a nurse practitioner (NP) at Children's Mercy Kansas City Dermatology, explained the roles that NPs and advanced practice providers (APPs) can fulfill in ensuring the efficiency of triage systems in a pediatric dermatology clinic.

Posters presented at the Society for Pediatric Dermatology Annual Meeting found that pediatric deroofing can lead to patient satisfaction later in life.

Kelly Harris, APRN, an advanced practice registered nurse at Cincinnati Children's Hospital Medical Center, discusses using mobile care units to deliver dermatology care and education to underserved communities and how health systems can implement them.

At the Society for Pediatric Dermatology annual conference, Faye Brown, MSN, APRN, FNP-BC, a family nurse practitioner at the University of Colorado School of Medicine, highlights how telemedicine efforts can be utilized within dermatology triage systems to better care for pediatric patients.

James Treat, MD, goes over some of the ways food can impact patients' atopic dermatitis, as well as the pros and cons of elimination diets to mitigate food-related triggers.

Updates in nonsteroidal topical therapies were presented during a session at the Society for Pediatric Dermatology Annual Meeting.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

A presentation at the Society for Pediatric Dermatology Annual Conference discussed how to use generative artificial intelligence (AI) to improve processes while working in the dermatology space.

Peter Lio, MD, a dermatologist and clinical assistant professor at Northwestern Feinberg School of Medicine, discusses strategies for managing pediatric atopic dermatitis and how proper management can impact the disease course.

Jennifer Miller, MD, a pediatric endocrinologist at Lurie Children's Hospital, discusses the challenges of systemic corticosteroid use in children, such as adrenal suppression and growth delays.

The Society for Pediatric Dermatology (SPD) Annual Meeting featured a new debates segment where experts in the field discussed preferred strategies for the treatment of pediatric skin conditions.

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo.

The annual meeting will take place in Toronto July 11-15, 2024.

Timothy Caulfield, JD, discusses the sessions he's most looking forward to at this year's Society for Pediatric Dermatology annual meeting, including his talk on overcoming misinformation in pediatric dermatology.

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

Pain improvement was associated with remission or low disease activity in patients undergoing treatment for rheumatoid arthritis, a study found.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses the hopeful future of treatment in idiopathic hypersomnia.

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.